{"created":"2023-05-15T08:55:10.323051+00:00","id":68,"links":{},"metadata":{"_buckets":{"deposit":"f79468e0-7f0e-4305-92b1-cb517e2d683e"},"_deposit":{"created_by":3,"id":"68","owners":[3],"pid":{"revision_id":0,"type":"depid","value":"68"},"status":"published"},"_oai":{"id":"oai:yachts.repo.nii.ac.jp:00000068","sets":["6:29:38"]},"author_link":["1928","1930","1927","1929","1926","1931"],"item_2_alternative_title_18":{"attribute_name":"その他の言語のタイトル","attribute_value_mlt":[{"subitem_alternative_title":"An Investigation Concerning the Expression of HER2 (Human Epidermal Growth Factor Receptor 2) on Breast Carcinoma in Yamagata Area"}]},"item_2_alternative_title_19":{"attribute_name":"タイトル（ヨミ）","attribute_value_mlt":[{"subitem_alternative_title":"ヤマガタケンノニュウガンノビョウリガクテキトクセイ : HER2 HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 ノハツゲンリツ ニカンスル チョウサ"}]},"item_2_biblio_info_6":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2010-01-01","bibliographicIssueDateType":"Issued"},"bibliographicPageEnd":"69","bibliographicPageStart":"61","bibliographicVolumeNumber":"13","bibliographic_titles":[{"bibliographic_title":"山形保健医療研究 = Yamagata Journal of Health Sciences"}]}]},"item_2_description_42":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"subitem_description":"論文(Article)","subitem_description_type":"Other"}]},"item_2_description_5":{"attribute_name":"内容記述","attribute_value_mlt":[{"subitem_description":"Abstract：Human epidermal growth factor receptor 2 (HER2) is a tyrosine kinase type receptor glycoprotein, which is overexpressed for some patients with breast carcinoma (BC). HER2 status should be incorporated into a clinical decision concerning BC treatment along with other clinicopathologic factors, because it has emerged that HER2 overexpression is associated with not only effectiveness of the newly developed antibody-therapy using trastuzumab, which targets for HER2, but also clinical outcomes of BC patients and sensitivity to different types of chemotherapeutic agents. In order to evaluate actual situation of diagnosis and treatment for BC in Yamagata prefecture, we reviewed practice and procedure on BC treatment, especially examination and results on HER2 status, using our original questionnaire in the present study. Consequently, the following results were obtained: 1) Actual number of BC cases treated with surgery was markedly increased during last 8 years in Yamagata prefecture. 2) HER2 positive rate in this area was appropriate 10.6 %, which appeared to be lower than other areas. 3) Concerning distribution of HER2 status, there was somewhat a difference between each hospital. To establish more adequate circumstance for BC treatment, accurate examination on HER2 status and the construction of the appropriate quality control system should be required. Key words：HER2/neu, c-erbB-2, immunohistochemistry (IHC)，fluorescence in situhybridization (FISH)，trastuzumab (Hercepti)","subitem_description_type":"Other"}]},"item_2_full_name_3":{"attribute_name":"著者別名","attribute_value_mlt":[{"nameIdentifiers":[{"nameIdentifier":"1929","nameIdentifierScheme":"WEKO"}],"names":[{"name":"MAEDA,  Kunihiko"}]},{"nameIdentifiers":[{"nameIdentifier":"1930","nameIdentifierScheme":"WEKO"}],"names":[{"name":"NINOMIYA,  Yukari"}]},{"nameIdentifiers":[{"nameIdentifier":"1931","nameIdentifierScheme":"WEKO"}],"names":[{"name":"MATSUDA,  Mikio"}]}]},"item_2_publisher_32":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"山形県立保健医療大学"}]},"item_2_source_id_9":{"attribute_name":"書誌レコードID","attribute_value_mlt":[{"subitem_source_identifier":"AA11209872","subitem_source_identifier_type":"NCID"}]},"item_2_text_33":{"attribute_name":"出版者（ヨミ）","attribute_value_mlt":[{"subitem_text_value":"ヤマガタ ケンリツ ホケン イリョウ ダイガク"}]},"item_2_text_34":{"attribute_name":"別言語の出版者","attribute_value_mlt":[{"subitem_text_value":"Yamagata Prefectural University of Health Sciences"}]},"item_2_text_43":{"attribute_name":"資源タイプ・ローカル","attribute_value_mlt":[{"subitem_text_value":"紀要論文"}]},"item_2_text_44":{"attribute_name":"資源タイプ・NII","attribute_value_mlt":[{"subitem_text_value":"Departmental Bulletin Paper"}]},"item_2_text_45":{"attribute_name":"資源タイプ・DCMI","attribute_value_mlt":[{"subitem_text_value":"text"}]},"item_2_text_46":{"attribute_name":"資源タイプ・ローカル表示コード","attribute_value_mlt":[{"subitem_text_value":"2"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"前田,  邦彦"}],"nameIdentifiers":[{"nameIdentifier":"1926","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"二宮,  ゆかり"}],"nameIdentifiers":[{"nameIdentifier":"1927","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"松田,  幹夫"}],"nameIdentifiers":[{"nameIdentifier":"1928","nameIdentifierScheme":"WEKO"}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2016-10-20"}],"displaytype":"detail","filename":"山形県の乳癌の病理学的特性.pdf","filesize":[{"value":"415.9 kB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"ypuhs-13-06.html","url":"https://yachts.repo.nii.ac.jp/record/68/files/山形県の乳癌の病理学的特性.pdf"},"version_id":"d7376092-3b17-47de-9cd7-5c3a6f8814cf"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"jpn"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"departmental bulletin paper","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"山形県の乳癌の病理学的特性 : HER2 (human epidermal growth factor receptor 2)の発現率に関する調査","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"山形県の乳癌の病理学的特性 : HER2 (human epidermal growth factor receptor 2)の発現率に関する調査"}]},"item_type_id":"2","owner":"3","path":["38"],"pubdate":{"attribute_name":"公開日","attribute_value":"2010-12-10"},"publish_date":"2010-12-10","publish_status":"0","recid":"68","relation_version_is_last":true,"title":["山形県の乳癌の病理学的特性 : HER2 (human epidermal growth factor receptor 2)の発現率に関する調査"],"weko_creator_id":"3","weko_shared_id":3},"updated":"2023-05-15T09:00:07.100403+00:00"}